Clinicians, researchers and scientists from around the world
will gather for Digestive Disease Week® 2010 (DDW), the largest
and most prestigious gastroenterology meeting, from May 1 to May 5,
2010, at the Ernest N. Morial Convention Center, New Orleans, LA.
DDW is the annual meeting of the American Gastroenterological
Association (AGA) Institute, the largest and oldest GI society in
the world. AGA researchers will present exciting, cutting-edge data
during the meeting that will help change the way physicians
diagnose and treat GI disorders.
All data presented during DDW is embargoed until the beginning
of the presentation or an official DDW press conference, whichever
occurs first. Go to www.ddw.org for a list of press
conferences.
Late-Breaking Session
On Tuesday, May 4 from 2:15 to 3:45 p.m. CT, Ballroom C, the AGA
will feature its late-breaking clinical abstracts, which include
exciting data on:
- A Randomized Placebo-controlled Trial of MDX-1100, an
Anti-IP-10 Antibody, for Moderately-to-Severely Active Ulcerative
Colitis. L. Mayer et al. (2:15 p.m.)
- Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of
Nitazoxanide plus Peginterferon and Ribavirin in Naïve
Patients with Chronic Hepatitis C Genotype 1 Infection: Final
Report. B. Bacon et al. (2:30 p.m.)
- Randomized Clinical Trial in Clostridium difficile Infection
Confirms Superiority of Fidaxomicin over Vancomycin. S. Johnson et
al. (2:45 p.m.)
- Prospective Clinical Validation of an Assay for Methylated
SEPT9 DNA in Human Plasma as a Colorectal Cancer Screening Tool in
Average Risk Men and Women 50 Years and Older. T. Church et al.
(3:00 p.m.)
- A Prospective, Multicentre Study to Evaluate a Novel
Non-Endoscopic Screening Device for Barrett's Esophagus in the
Community Setting. S. Kadri et al. (3:15 p.m.)
- Multi-Modality Endoscopic Therapy for Complete Eradication of
Barrett's Esophagus. N. Gupta et al. (3:30 p.m.)
Plenary Sessions
During the Presidential Plenary Session, AGA Institute
President, Gail A. Hecht, MD, MS, AGAF, will focus on critical
questions for gastroenterology. Two concurrent plenary sessions
feature noteworthy clinical and basic science research presented at
DDW.
The Presidential Plenary session presentations (Monday, May 3,
10 a.m. to noon CT, Auditorium AB) include:
- Celiac Disease Therapy and Novel Approaches. C. Kelly (10:09
a.m.)
- Evaluating IBD: Outcomes and Complications. M. Abreu (10:19
a.m.)
- Major Advances in IBS. L. Chang (10:29 a.m.)
- Eosinophilic Esophagitis: Challenges and Horizons. G. Furuta
(10:39 a.m.)
- Gastric Disease in the 21st Century: A Tale of Three Stomachs.
T. Wang (10:49 a.m.)
- Microbiota in Digestive Health — Promise, Prospects and
Pragmatism. F. Shanahan (10:59 a.m.)
- Obesity and Bariatrics for the Endoscopist: New Techniques. C.
Thompson (11:09 a.m.)
- Medical Management of NAFLD. A. Diehl (11:19 a.m.)
- Era of Health-care Reform: What Is the Impact on GI? J. Inadomi
(11:29 a.m.)
The Clinical Plenary session presentations (Monday, May 3, 8 to
10 a.m. CT, Auditorium AB) include:
- UK Flexible Sigmoidoscopy Screening Trial: Colorectal Cancer
Incidence and Mortality Rates at 11 Years After a Single Screening
Examination. W. Atkin et al. (8:05 a.m.)
- Laparoscopic Antireflux Surgery vs Long-Term Esomeprazole
Treatment for Chronic GERD. Final Results After 5 Yrs of Follow up
in the Lotus Study. J.P. Galmiche et al. (8:20 a.m.)
- The European Achalasia Trial: A Randomized Multi-Centre Trial
Comparing Endoscopic Pneumodilation and Laparoscopic Myotomy As
Primary Treatment of Idiopathic Achalasia. G. Boeckxstaens et al.
(8:35 a.m.)
- Efficacy and Safety of Once Daily Linaclotide Administered
Orally for 12-Weeks in Patients With Chronic Constipation: Results
From 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials.
A. Lembo et al. (8:50 a.m.)
The Basic Science Plenary session presentations (Monday, May 3,
8 to 10 a.m. CT, Room 393-396) include:
- Altered Gut Microbiota in Toll-Like Receptor-5 (TLR5) Deficient
Mice Results in Metabolic Syndrome. M. Vijay-Kumar et al. (8:05
a.m.)
- Leptin Resistance in Vagal Afferent Neurons Leads to Decreased
Cholecystokinin Signaling in Diet-Induced Obese Rats. G. de
Lartigue et al. (8:22 a.m.)
- Regulation of Food Intake in Diet-Induced Obesity. L. Kaplan
(8:39 a.m.)
- Characterization of Slowly Cycling Telomerase-Expressing
Intestinal Stem Cells. C. Richmond et al. (9:04 a.m.)
- The Crohn's Disease Protective SNP Rs11209026 Allele "a"
Mediates Alternative Splicing in Human IL23R Transcription. R. Yu
et al. (9:21 a.m.)
Other exciting data will be presented during DDW, including 36
clinical symposia, 11 translational symposia, 14 research symposia
and eight state-of-the-art lectures on a range of GI topics.
Additionally, the AGA Institute will sponsor eight curbside
consultant sessions. Eight focused research roundtables and 14
focused clinical updates — breakfast sessions designed to
help participants choose the must-see basic science and clinical
research abstracts presented during DDW — will occur
throughout the meeting.
AGA Digestive Health Outcomes Registry™
DDW marks the launch of the AGA Digestive Health
Outcomes Registry™, a revolutionary national outcomes-driven
registry. It allows gastroenterologists to monitor and improve
patient care, while also generating data to compare the efficacy of
treatments and potentially increase reimbursement. The AGA Registry
launches with an initial focus on IBD and colorectal cancer
prevention.
On Wednesday, May 5, from 8:30 to 10 a.m., the physicians who
created the registry will lead a session in rooms 280-282 to cover
topics, including what is a data registry and why participate,
limits and potential pitfalls of a data registry, registry reports,
and how registries can impact public health of underrepresented
populations.
ROME Foundation-AGA Institute Lectureship
Erwin G. Zoetendal, MD, assistant professor in the
agrotechnology and food sciences laboratory of microbiology at
Wageningen University, the Netherlands, will shed light on the
mysteries of gut microbiota as the invited lecturer during
Tuesday's third annual Rome Foundation-AGA Institute Lectureship
(10:30 to 11:30 a.m. CT, Room 391/392). His talk, "Understanding
Gut Microbiota: A New Era in Gastroenterology," will provide an
overview of gastrointestinal tract microbiota diversity by
discussing culture-independent approaches to study microbiota
diversity in relation to health and disease — including
functional gastrointestinal disorders — as well as
culture-independent approaches to study microbiota genetic
potential and activity.
Douglas Drossman, MD, AGAF, Rome Foundation president, said the
Rome Foundation and the AGA Institute are honored to have Dr.
Zoetendal present this year's lecture. "There are huge numbers of
bacteria living in harmony within every human organism. And this is
the guy who understands best how different types affect the gut
inside and out. He is a translational scientist who will help our
members better understand when to use probiotics and when not
to."
SOURCE